期刊
CELL DEATH AND DIFFERENTIATION
卷 14, 期 4, 页码 851-860出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.cdd.4402077
关键词
PKC epsilon; TRAIL; Bcl-2; Bid; apoptosis; breast cancer
资金
- NATIONAL CANCER INSTITUTE [R01CA071727] Funding Source: NIH RePORTER
- NCI NIH HHS [CA71727] Funding Source: Medline
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent as it selectively kills tumor cells but spares normal cells. Resistance to TRAIL by tumor cells limits its therapeutic use. We have previously shown that protein kinase C-epsilon (PKC epsilon) acts as an antiapoptotic protein in MCF-7 breast cancer cells. In the present study, we have investigated the mechanism(s) by which PKCe contributes to TRAIL resistance. Overexpression of PKCe inhibited caspase-8 and -9 activation, release of mitochondrial cytochrome c and cell death induced by TRAIL, but did not interfere with the recruitment of caspase-8 to the death-inducing signaling complex. Knockdown/inhibition of PKCe resulted in enhanced sensitivity to TRAIL. The level of Bcl-2 was increased and Bid was decreased by PKCe at both the protein and mRNA level but PKCe had no effect on Bax. Knockdown of Bcl-2 by siRNA reversed TRAIL resistance in PKC epsilon-overexpressing cells, whereas depletion of Bid contributed to TRAIL resistance in MCF-7 cells. A decrease in Bid content was also associated with inhibition of TRAIL-induced caspase-8 activation. Furthermore, PKC epsilon depletion or overexpression of DN-PKC epsilon was associated with a decrease in Bcl-2 protein level. Thus, our results suggest that PKC epsilon acts upstream of mitochondria and mediates TRAIL resistance via both Bcl-2 and Bid in MCF-7 cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据